Value of serum glucagon like peptide-1 detection in assessment of Alzheimer's disease
Objective: To study the value of serum glucagon like peptide-1 detection in assessment of Alzheimer’s disease. Methods: A total of 35 cases of patients with Alzheimer’s disease were enrolled in AD group, 35 cases of patients with type 2 diabetes mellitus were enrolled in T2DM group, 35 cases of A...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Editorial Board of Journal of Hainan Medical University
2016-02-01
|
| Series: | Journal of Hainan Medical University |
| Subjects: | |
| Online Access: | http://www.jhmuweb.net/PDF/201604/24.pdf |
| Summary: | Objective: To study the value of serum glucagon like peptide-1 detection in assessment of
Alzheimer’s disease. Methods: A total of 35 cases of patients with Alzheimer’s disease were
enrolled in AD group, 35 cases of patients with type 2 diabetes mellitus were enrolled in T2DM
group, 35 cases of Alzheimer’s disease patients complicated with type 2 diabetes mellitus were
enrolled in AD+T2DM group, and 35 cases of healthy subjects were enrolled in control group.
Serum was collect to detect A β, Tau, GLP-1, IL-1β, IL-6, TNF-α, IFN-γ, MDA, AOPP,
SOD and GSH contents. Results: Contents of serum A β(1-42) and Tau protein, content of
GLP-1 after taking glucose as well as contents of IL-1 β, IL-6, TNF-α, IFN-γ, MDA, AOPP,
SOD and GSH of four groups had differences; contents of serum A β(1-42), Tau protein as
well as contents of IL-1 β, IL-6, TNF-α, IFN-γ, MDA and AOPP of AD group, T2DM
group and AD+T2DM group were higher than those of control group, content of GLP-1 after
taking glucose and SOD, GSH contents were lower than those of control group, and changes
of above indexes in serum of AD+T2DM group were more significant than those of AD group
and T2DM group; 0.5 h, 1.0 h, 1.5 h and 2.0 h after taking glucose, serum GLP-1 content was
negatively correlated with serum A β(1-42) and Tau protein contents. Conclusion: After taking
glucose, serum glucagon like peptide-1 content decreases in patients with Alzheimer’s disease,
and it has assessed value in changes of A β(1-42) and Tau protein contents as well as degree of
inflammation and oxidative stress. |
|---|---|
| ISSN: | 1007-1237 1007-1237 |